Clinical trial

Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer

NCT05169853

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2022-01-01

PhaseN/A

Study timeline

Study start (actual)2022-01-01Date precision: day

Registry last updated2024-08-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Cancerunresolved

HER2-positive Breast Cancerunresolved

Interventions

Sponsors & collaborators

Ain Shams Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05169853 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.